"Maybe we should think of COVID-19 as a heart disease."
Apologies if today's article is already posted.
You will recall that a number of secondary outcome measures in our Rem-L COVID-19 trial relate to serum hs-CRP (High-sensitivity C-reactive Protein) testing. A test to assess, inter alia, cardiovascular disease. Of course they were, given Silviu's background. Legend.
https://www.statnews.com/2020/09/04/carnage-in-lab-dish-shows-how-coronavirus-may-damage-heart/?utm_source=STAT+Newsletters&utm_campaign=eeb957f81c-Daily_Recap&utm_medium=email&utm_term=0_8cab1d7961-eeb957f81c-152585569
And the report: https://www.biorxiv.org/content/10.1101/2020.08.25.265561v1
"COVID-19 causes cardiac dysfunction in up to 50% of patients, but the pathogenesis remains unclear."
Really? Just ask the Doc about MOA - Rem-L / Revascor. He knows.
Looking forward to the trial read outs, hoping for early "Q4 CY2020".
Have a great weekend, and Dads' Day.
GLTAH!
Cell Therapy News/Articles, page-6262
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |